» Articles » PMID: 15112303

Survival Analysis in Patients with Glioblastoma Multiforme: Predictive Value of Choline-to-N-acetylaspartate Index, Apparent Diffusion Coefficient, and Relative Cerebral Blood Volume

Overview
Date 2004 Apr 28
PMID 15112303
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To investigate the potential value of pre-external-beam radiation therapy (XRT) choline-to-NAA (N-acetylaspartate) index (CNI), apparent diffusion coefficient (ADC), and relative cerebral blood volume (rCBV) for predicting survival in newly diagnosed patients with glioblastoma multiforme (GBM).

Materials And Methods: Twenty-eight patients with GBM were studied using in vivo proton magnetic resonance spectroscopic imaging (1H MRSI) and diffusion- and perfusion-weighted imaging after surgery but prior to XRT. Patients were categorized on the basis of their volumes of morphologic and metabolic abnormalities (volume of CNI > or = 2 and CNI values), normalized ADC (nADC), or rCBV values within the T1 contrast-enhancing and T2 regions. The median survival time was compared.

Results: A significantly shorter median survival time was observed for patients with a large volume of metabolic abnormality than for those with a small abnormality (12.0 and 17.1 months, respectively, P = 0.002). A similar pattern was observed for patients with a low mean nADC value compared to those with high mean nADC value within the T2 region (11.2 and 21.7 months, respectively, P = 0.004). A shorter median survival time was also observed for patients with contrast-enhancing residual disease than for those without the presence of contrast enhancement with marginal significance.

Conclusion: The pre-XRT volume of the metabolic abnormality and the nADC value within the T2 region may be valuable in predicting outcome for patients with GBM.

Citing Articles

Integrating multi-modal imaging in radiation treatments for glioblastoma.

Breen W, Aryal M, Cao Y, Kim M Neuro Oncol. 2024; 26(12 Suppl 2):S17-S25.

PMID: 38437666 PMC: 10911793. DOI: 10.1093/neuonc/noad187.


Mapping of exogenous choline uptake and metabolism in rat glioblastoma using deuterium metabolic imaging (DMI).

Ip K, Thomas M, Behar K, de Graaf R, De Feyter H Front Cell Neurosci. 2023; 17:1130816.

PMID: 37187610 PMC: 10175635. DOI: 10.3389/fncel.2023.1130816.


Peritumoral ADC Values Correlate with the MGMT Methylation Status in Patients with Glioblastoma.

Ladenhauf V, Galijasevic M, Kerschbaumer J, Freyschlag C, Nowosielski M, Birkl-Toeglhofer A Cancers (Basel). 2023; 15(5).

PMID: 36900177 PMC: 10000073. DOI: 10.3390/cancers15051384.


Delineation of recurrent glioblastoma by whole brain spectroscopic magnetic resonance imaging.

Bell J, Jin W, Goryawala M, Azzam G, Abramowitz M, Diwanji T Radiat Oncol. 2023; 18(1):37.

PMID: 36814267 PMC: 9948314. DOI: 10.1186/s13014-023-02219-2.


DCE-MRI and DWI can differentiate benign from malignant prostate tumors when serum PSA is ≥10 ng/ml.

Sun H, Du F, Liu Y, Li Q, Liu X, Wang T Front Oncol. 2022; 12:925186.

PMID: 36578948 PMC: 9792168. DOI: 10.3389/fonc.2022.925186.